|
|
| 26-Feb-2001 |
Endovasc Announces Completion of Dog Studies for Nicotine Receptor Agonist
|
|
MONTGOMERY, Texas--(BW HealthWire)--Feb. 26, 2001--
Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced the completion of further studies of its Nicotine Receptor Agonist (NRA) in dogs.
NRA has been proven to create new blood vessel growth (angiogenesis) in animals. Dr. Daniel Burkhoff, associate professor of medicine in the Division of Circulatory Physiology at Columbia University's College of Physicians and Surgeons, and an associate attending physician at the New York Presbyterian Hospital, has completed recent testing of NRA in dogs. With the positive results from the studies, Dr. Burkhoff will proceed with ischemic pig models, a study which is projected for completion in approximately 10 weeks.
The company is continuing animal studies and human clinical trials for the use of NRA as a non-surgical angiogenic therapy for blocked arteries to the heart, avoiding angioplasty and possibly even by-pass surgeries for this condition. According to Dr. David P. Summers, chairman and CEO of Endovasc, "The use of NRA could create a 'biological by-pass' therapy, a revolutionary methodology for treating ischemic heart disease."
Dr. Antonio Colombo, chief of investigational angioplasty at Lenox Hill Hospital in New York, and director of the cardiac catheterization laboratory at EMO Centro Cuore Columbus in Milan, will conduct the human pilot study for NRA in Italy in March of this year. This clinical trial will involve patients with diseased heart muscle resulting from a deficiency of blood caused by obstruction in the blood vessel (ischemic cardiomyopathy) and chronic or uncontrolled chest pain (intractable angina pectoris).
Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company's products and processes, which include Liprostin™ (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology, and a biodegradable/resorbable stent, are covered by patents and trade secrets for competing in a multi-billion dollar market.
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc.
Contact:
Endovasc Ltd. Inc.,
Jack Sorbi,
936/448-2222
jack@endovasc.com
www.endovasc.com
|
|
|
|
|
